Approval of Aducanumab for Alzheimer Disease-The FDA's Perspective

Uložené v:

Podrobná bibliografia
Vydané v:	JAMA internal medicine Ročník 181; číslo 10; s. 1276
Hlavní autori:	Dunn, Billy, Stein, Peter, Cavazzoni, Patrizia
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.10.2021
Predmet:	Alzheimer Disease - diagnosis Alzheimer Disease - drug therapy Amyloid beta-Peptides - antagonists & inhibitors Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - economics Brain - diagnostic imaging Brain - pathology Decision Making Dose-Response Relationship, Drug Drug Approval - methods Humans Infusions, Intravenous - methods Magnetic Resonance Imaging - methods Nootropic Agents - administration & dosage Nootropic Agents - adverse effects Nootropic Agents - economics Plaque, Amyloid - diagnostic imaging Positron-Emission Tomography - methods Product Surveillance, Postmarketing Randomized Controlled Trials as Topic - methods Treatment Outcome United States United States
ISSN:	2168-6114, 2168-6114
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!